Glutamatergic Dysfunction-Newer Targets for Anti-Obsessional Drugs
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Despite widespread use and validation of their efficacy, about 40-60% of obsessive compulsive disorder (OCD) sufferers do not respond to appropriate courses of treatment with serotonin reuptake inhibitors (SRI) and even with the combination of pharmacotherapy and cognitive behaviour therapy a substantial number of patients remain dramatically symptomatic. Recently, there has been increasing interest in investigating glutamatergic dysfunction in OCD. Multiple lines of evidence point toward glutamatergic dysfunction being related to the pathophysiology of OCD, with glutamate modulating drugs being an alternative pharmacological strategy for treating OCD. In this article we focus in detail on the rationale for targeting glutamatergic agents as well as review the recent important patents for compounds that have emerged from these studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toward a neurobiology of obsessive-compulsive disorder
Graybiel, A. M., & Rauch, S. L. (2000) · Neuron · doi:10.1016/s0896-6273(00)00113-6 · Cited by 864 · cited 1×
“This circuit involves a complex neurotransmitter network, where dopamine, serotonin, glutamate, and GABA dysfunction have been implicated in OCD [ 30 ].”
BackgroundNeuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
A Family Study of Obsessive-compulsive Disorder
Nestadt, G., Samuels, J., Riddle, M., Bienvenu, O. J., Liang, K.-Y., LaBuda, M., Walkup, J., Grados, M., & Hoehn-Saric, R. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.4.358 · Cited by 657
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
The genetics of schizophrenia and bipolar disorder: dissecting psychosis
Craddock, N., O’Donovan, M. C., & Owen, M. J. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.030718 · Cited by 574
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Stein, D. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09620-4 · Cited by 352
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · cited 2×
“Evidence has also been accumulating in recent years of the effectiveness of glutamate-modulating agents in the treatment of OCD.”
BackgroundResultSelf-citationObsessive-compulsive disorder and serotonin: Is there a connection?
Insel, T. R., Mueller, E. A., Alterman, I., Linnoila, M., & Murphy, D. L. (1985) · Biological Psychiatry · doi:10.1016/0006-3223(85)90176-3 · Cited by 343 · cited 1×
“1574-8898/07 $100.00+.00 © 2007 Bentham Science Publishers Ltd. Keywords: Glutamate, serotonin, obsessive compulsive disorder, metabotropic glutamate receptor antagonist.”
BackgroundInfluentialEvidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Szechtman, H., Sulis, W., & Eilam, D. (1998) · Behavioral Neuroscience · doi:10.1037/0735-7044.112.6.1475 · Cited by 315
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 1×
“…mice with increased glutamate output to the striatum exhibited a phenotype similar to comorbid OCD and Tourette syndrome including generalized behavioural perseveration, compulsive leaping, grooming-associated pulling and biting of skin and hair (similar to trichotillomania), and tics [54].”
BackgroundDickel, D. E., Veenstra-VanderWeele, J., Cox, N. J., Wu, X., Fischer, D. J., Van Etten-Lee, M., Himle, J. A., Leventhal, B. L., Cook, E. H., & Hanna, G. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.7.778 · Cited by 274 · cited 1×
“In a later study from the same group, there was however decrease in the absolute Glx level in the anterior cingulate of children with OCD [36].”
BackgroundROSENBERG, D. R., MIRZA, Y., RUSSELL, A., TANG, J., SMITH, J. M., BANERJEE, S. P., BHANDARI, R., ROSE, M., IVEY, J., BOYD, C., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000132812.44664.2d · Cited by 246
Arnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202 · cited 1×
“Subsequently, Rosenberg et al. (2000) [34] studied 11 psychotropic drug-naïve children with OCD, with single-voxel 1H-MRS examinations and demonstrated that caudate Glx concentrations were significantly greater in the patients compared to healthy controls.”
BackgroundCampbell, K. M., de Lecea, L., Severynse, D. M., Caron, M. G., McGrath, M. J., Sparber, S. B., Sun, L.-Y., & Burton, F. H. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-12-05044.1999 · Cited by 170 · cited 2×
“Clinical studies [20, 21] as well as animal models of OCD [22, 23 ] and findings from imaging studies [13,15,24, 25] have also suggested the presence of dopaminergic dysfunction in OCD.”
BackgroundMethodLeckman, J. F., Goodman, W. K., Anderson, G. M., Riddle, M. A., Chappell, P. B., McSwiggan-Hardin, M. T., McDougle, C. J., Scahill, L. D., Ort, S. I., Pauls, D. L., et al. (1995) · Neuropsychopharmacology · doi:10.1038/sj.npp.1380241 · Cited by 169 · cited 4×
“There is a growing body of literature from imaging [12-16], cerebrospinal fluid (CSF) [6,17,18] and pharmacological challenge stu-dies [19] supporting the serotonergic dysfunction hypothesis in OCD.”
BackgroundInfluentialCurrent animal models of obsessive compulsive disorder: a critical review
Joel, D. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.006 · Cited by 168 · cited 1×
“MPEP was noted to have a significant effect in the marble burying test, a well-known animal model of OCD [78], in addition to its effect on various other animal models of anxiety.”
BackgroundSerotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder
Hesse, S., Müller, U., Lincke, T., Barthel, H., Villmann, T., Angermeyer, M. C., Sabri, O., & Stengler-Wenzke, K. (2005) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2005.07.002 · Cited by 155 · cited 1×
“It has a lifetime prevalence of 1.9- 2.5 % across multinational sites [1] which is about twice the lifetime prevalence rates of schizophrenia [2].”
BackgroundInfluentialvan der Wee, N. J., Stevens, H., Hardeman, J. A., Mandl, R. C., Denys, D. A., van Megen, H. J., Kahn, R. S., & Westenberg, H. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2201 · Cited by 149 · cited 1×
“Clinical studies [20, 21] as well as animal models of OCD [22,23] and findings from imaging studies [13,15,24, 25] have also suggested the presence of dopaminergic dysfunction in OCD.”
BackgroundAdams, K. H., Hansen, E. S., Pinborg, L. H., Hasselbalch, S. G., Svarer, C., Holm, S., Bolwig, T. G., & Knudsen, G. M. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005055 · Cited by 147 · cited 1×
“There is a growing body of literature from imaging [12-16], cerebrospinal fluid (CSF) [6,17,18] and pharmacological challenge stu-dies [19] supporting the serotonergic dysfunction hypothesis in OCD.”
BackgroundThe role of central oxytocin in obsessive compulsive disorder and related normal behavior
Leckman, J. F., Goodman, W. K., North, W. G., Chappell, P. B., Price, L. H., Pauls, D. L., Anderson, G. M., Riddle, M. A., McDougle, C. J., Barr, L. C., et al. (1994) · Psychoneuroendocrinology · doi:10.1016/0306-4530(94)90021-3 · Cited by 133 · cited 1×
“Because of its high prevalence rates and the disabling nature of its symptoms, OCD has been named by the World Health Organization among the top 10 causes of years lived with illness-related disability [3].”
BackgroundMOORE, G. J., MACMASTER, F. P., STEWART, C., & ROSENBERG, D. R. (1998) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199806000-00017 · Cited by 85
Kim, C.-H., Koo, M.-S., Cheon, K.-A., Ryu, Y.-H., Lee, J.-D., & Lee, H.-S. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1245-7 · Cited by 82 · cited 1×
“It has a lifetime prevalence of 1.9- 2.5 % across multinational sites [1] which is about twice the lifetime prevalence rates of schizophrenia [2].”
BackgroundInfluential
Cited by
Brimberg, L., Benhar, I., Mascaro-Blanco, A., Alvarez, K., Lotan, D., Winter, C., Klein, J., Moses, A. E., Somnier, F. E., Leckman, J. F., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.56 · Cited by 202
“Fourth, we examined rat brains for antibody deposition (expected), gross neural damage (not expected), and changes in the dopaminergic, serotonergic, glutamatergic, and GABAergic systems, which have been implicated in the pathophysiology of motor and tic disorders and OCD (Bhattacharyya and Chakraborty, 2007; Singer a…”
BackgroundRolls, E. T. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.017 · Cited by 39
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Adenylate-cyclase activity in platelets of patients with obsessive-compulsive disorder
Marazziti, D. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4956 · Cited by 3
Metadata
- Authors
- Bhattacharyya, S., & Chakraborty, K.
- Venue
- Recent Patents on CNS Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2007-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 47-55
- ISSN
- 1574-8898 (ISSN-L)
- OpenAlex
- W2061593669
- Cited by
- 39
- References
- 24
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.